Recursion Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75629V1044

SecurityRXRX / Recursion Pharmaceuticals, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership624,659 shares
Latest Disclosed Value $ 1,917,703
Citadel Advisors Llc ownership in RXRX / Recursion Pharmaceuticals, Inc.

On May 15, 2026 - Citadel Advisors Llc filed a 13F-HR form disclosing ownership of 624,659 shares of Recursion Pharmaceuticals, Inc. (US:RXRX) valued at $1,917,703 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 4,229,999 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of -85.23% during the quarter. The current value of the position is $2,167,567 USD.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (RXRX) in the form of stock options. The firm currently holds call options representing 1,009,800 of underlying shares valued at $3,100,086 USD and put options representing 798,900 of underlying shares valued at $2,452,623 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

RXRX / Recursion Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 624,659 -3,605,340 -85.23 1,918 -88.92 0.0003
2026-02-17 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 4,229,999 2,881,315 213.64 17,301 162.88 0.0026
2025-11-14 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,348,684 34,132 2.60 6,582 -1.05 0.0010
2025-08-14 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,314,552 -1,341,159 -50.50 6,652 -52.66 0.0012
2025-05-15 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 2,655,711 -83,536 -3.05 14,049 -24.13 0.0027
2025-02-14 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 2,739,247 2,505,024 1,069.50 18,517 1,100.06 0.0032
2024-11-14 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 234,223 -510,856 -68.56 1,544 -72.39 0.0003
2024-08-14 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 745,079 404,705 118.90 5,588 64.69 0.0011
2024-05-15 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 340,374 303,880 832.68 3,394 845.13 0.0007
2024-02-14 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 36,494 -266,596 -87.96 360 -84.51 0.0001
2023-11-14 2023-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 303,090 -434,668 -58.92 2,319 -57.94 0.0005
2023-08-14 2023-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 737,758 132,243 21.84 5,511 36.48 0.0011
2023-05-15 2023-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 605,515 -165,635 -21.48 4,039 -32.08 0.0009
2023-02-14 2022-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 771,150 269,280 53.66 5,946 11.35 0.0014
2022-11-14 2022-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 501,870 194,498 63.28 5,339 113.39 0.0012
2022-08-15 2022-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 307,372 -602,598 -66.22 2,502 -61.60 0.0006
2022-05-16 2022-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 909,970 710,363 355.88 6,515 90.50 0.0013
2022-02-14 2021-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 199,607 199,607 3,420 0.0007
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 1,009,800 -48.97 3,100 -61.70 n/a n/a n/a
2026-02-17 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 1,978,800 1.84 8,093 -14.65 n/a n/a n/a
2025-11-14 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A Call 1,943,100 13.26 9,482 9.24 n/a n/a n/a
2025-08-14 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A Call 1,715,562 361.44 8,681 341.51 n/a n/a n/a
2025-05-15 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 371,787 -27.76 1,967 -43.47 n/a n/a n/a
2025-02-14 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 514,633 71.95 3,479 76.37 n/a n/a n/a
2024-11-14 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A Call 299,300 16.73 1,972 2.55 n/a n/a n/a
2024-08-14 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A Call 256,400 15.91 1,923 -12.79 n/a n/a n/a
2024-05-15 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 221,200 72.54 2,205 74.45 n/a n/a n/a
2024-02-14 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 128,200 62.90 1,264 109.97 n/a n/a n/a
2023-11-14 2023-09-30 13F RECURSION PHARMACEUTICALS IN CL A Call 78,700 213.55 602 221.93 n/a n/a n/a
2023-08-14 2023-06-30 13F RECURSION PHARMACEUTICALS IN CL A Call 25,100 13.06 187 26.35 n/a n/a n/a
2023-05-15 2023-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 22,200 16.23 148 0.68 n/a n/a n/a
2023-02-14 2022-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 19,100 0.53 147 -27.23 n/a n/a n/a
2022-11-14 2022-09-30 13F RECURSION PHARMACEUTICALS IN CL A Call 19,000 -34.03 202 -13.68 n/a n/a n/a
2022-08-15 2022-06-30 13F RECURSION PHARMACEUTICALS IN CL A Call 28,800 36.49 234 54.97 n/a n/a n/a
2022-05-16 2022-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 21,100 21.26 151 -49.33 n/a n/a n/a
2022-02-14 2021-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 17,400 -53.97 298 -65.75 n/a n/a n/a
2021-11-15 2021-09-30 13F RECURSION PHARMACEUTICALS IN Cmn Call 37,800 500.00 870 278.26 n/a n/a n/a
2021-08-16 2021-06-30 13F RECURSION PHARMACEUTICALS IN CL A Call 6,300 230 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A Put 798,900 -59.36 2,453 -69.50 n/a n/a n/a
2026-02-17 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A Put 1,965,600 80.30 8,039 51.11 n/a n/a n/a
2025-11-14 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A Put 1,090,200 55.98 5,320 50.45 n/a n/a n/a
2025-08-14 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A Put 698,947 -48.60 3,537 -50.84 n/a n/a n/a
2025-05-15 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A Put 1,359,885 3.90 7,194 -18.70 n/a n/a n/a
2025-02-14 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A Put 1,308,844 135.11 8,848 141.19 n/a n/a n/a
2024-11-14 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A Put 556,700 1.20 3,669 -11.08 n/a n/a n/a
2024-08-14 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A Put 550,100 131.82 4,126 74.42 n/a n/a n/a
2024-05-15 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A Put 237,300 180.83 2,366 183.91 n/a n/a n/a
2024-02-14 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A Put 84,500 1.20 833 30.56 n/a n/a n/a
2023-11-14 2023-09-30 13F RECURSION PHARMACEUTICALS IN CL A Put 83,500 956.96 639 981.36 n/a n/a n/a
2023-08-14 2023-06-30 13F RECURSION PHARMACEUTICALS IN CL A Put 7,900 -65.65 59 -61.44 n/a n/a n/a
2023-05-15 2023-03-31 13F RECURSION PHARMACEUTICALS IN CL A Put 23,000 1,669.23 153 1,430.00 n/a n/a n/a
2023-02-14 2022-12-31 13F RECURSION PHARMACEUTICALS IN CL A Put 1,300 -88.70 10 -91.80 n/a n/a n/a
2022-11-14 2022-09-30 13F RECURSION PHARMACEUTICALS IN CL A Put 11,500 -24.34 122 -1.61 n/a n/a n/a
2022-08-15 2022-06-30 13F RECURSION PHARMACEUTICALS IN CL A Put 15,200 124 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.